Background: Several international centres have published their experiences with outpatient autologous stem cell transplantation (ASCT) as treatment of haematological malignancies.
Aim: In this single-centre retrospective review, we aim to examine the outcomes of outpatient autograft and review healthcare resource utilisation in the pre-cytopenic period.
Methods: Patients undergoing ASCT in Royal Hobart Hospital, Tasmania between 2008 and 2018 had their records reviewed and key outcomes data collected based on whether they received inpatient/outpatient ASCT. An outpatient ASCT was defined as conditioning as an outpatient; patients could then be managed with an elective admission during the cytopenic period or admission only when clinically indicated.
Results: Of 231 ASCT performed, 135 (58%) were as outpatients: 59 used carmustine-etoposide-cytarabine-melphalan conditioning for lymphoma (BEAM-ASCT) and 76 used high-dose melphalan for myeloma and amyloidosis (MEL-ASCT). Approximately one-third of patients undergoing outpatient ASCT were admitted electively during nadir period; the majority of patients required minimal interventions prior to this time. The most common causes for unplanned hospitalisation (which occurred in 71 (80%) of the 89 planned outpatient transplants) were febrile neutropenia (39%) and mucositis (35%). Age was the only risk factor identified to increase risk of requiring unplanned hospitalisation. Use of oral antibiotic prophylaxis reduced febrile neutropenia rates among melphalan outpatient ASCT. Outpatient ASCT led to significantly reduced inpatient bed-days and overall cost (approximately A$13 000-A$16 000) compared with inpatient autografts, with no significant differences in engraftment, rates of febrile neutropenia, intensive care admissions or mortality.
Conclusion: Outpatient autografts may save healthcare resources without compromising patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/imj.15334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma.
Eur J Haematol
December 2024
Department of Oncology and Haematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany.
Background: Secondary malignancies are potential complications after high-dose therapy and autologous stem cell transplantation (ASCT). Information on the detailed course of such events is scarce, yet may be essential to minimize the impact of these sequelae.
Patients And Methods: We regularly monitored 877 patients for up to 31 years after ASCT in our outpatient department.
Comfort Care Needs of Allogeneic Stem Cell Transplant Survivors: Lived Experience.
Healthcare (Basel)
November 2024
Institute of Health Sciences e Center for Interdisciplinary Health Research, Universidade Católica Portuguesa, Palma de Cima, Edifício Reitoria, 1649-023 Lisboa, Portugal.
Introduction: Allogeneic Stem Cell Transplantation (ASCT) and, consequently, the chronicity associated with this life event have a growing prevalence and a significant impact on the life and daily life of each person who experiences it. It is necessary to reflect on the care needs of this group of vulnerable people. Comfort is a concern, and its improvement is a desired outcome of healthcare.
View Article and Find Full Text PDFAmbulatory models for autologous stem-cell transplantation: a systematic review of the health impact.
Front Immunol
July 2024
Hematology Department, Bone Marrow Transplantation Unit, Instituto del Cáncer y Enfermedades de la Sangre (ICAMS), Hospital Clínic, Barcelona, Spain.
Autologous stem-cell transplantation (ASCT) is the standard of care for the management of multiple myeloma and has a well-established role in the treatment of some types of lymphoma. Over the last decades, the number of ASCT performed has increased significantly, leading to elevated pressure and cost for healthcare services. Conventional model of ASCT includes the admission of patients to a specialized Transplant Unit at any stage of the procedure.
View Article and Find Full Text PDFHistorical Perspective of High-Dose Therapy Followed by Autologous Stem Cell Transplantation in Multiple Myeloma.
Acta Haematol
May 2024
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Background: High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) has become part of standard of care (SOC) in newly diagnosed multiple myeloma. In this review, we provide a historical perspective on ASCT since its introduction in the 1990s.
Summary: Overall survival (OS) benefit for HDT followed by ASCT was demonstrated in studies comparing HDT with ASCT to standard-dose therapy (SDT) before the era of novel agents.
Serum Levels of miR-122-5p and miR-125a-5p Predict Hepatotoxicity Occurrence in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation.
Int J Mol Sci
April 2024
Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Hepatic complications are an acknowledged cause of mortality and morbidity among patients undergoing hematopoietic stem cell transplantation. In this study, we aimed to evaluate the potential role in the prediction of liver injury of five selected microRNAs (miRNAs)-miR-122-5p, miR-122-3p, miR-15b-5p, miR-99b-5p, and miR-125a-5p-in the setting of autologous hematopoietic stem cell transplantation (ASCT). A total of 66 patients were included in the study: 50 patients (75.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!